Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.60 +2.9%	$4.52	$1.14 ▼ $7.20	$325.83M	0.76	992,421 shs	1.18 million shs
ARDX Ardelyx	$5.86 +0.9%	$4.44	$3.21 ▼ $7.18	$1.40B	0.68	4.43 million shs	4.67 million shs
AVDL Avadel Pharmaceuticals	$13.70 +1.6%	$10.58	$6.38 ▼ $16.66	$1.31B	1.47	1.18 million shs	720,388 shs
COGT Cogent Biosciences	$11.76 -2.9%	$9.99	$3.72 ▼ $12.97	$1.38B	0.36	1.72 million shs	866,280 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+2.94%	+4.48%	+3.90%	+148.89%	+3.90%
ARDX Ardelyx	+0.86%	+4.64%	+32.88%	+46.87%	-2.17%
AVDL Avadel Pharmaceuticals	+1.63%	+2.24%	+26.50%	+49.73%	-15.17%
COGT Cogent Biosciences	-2.89%	+1.82%	-5.84%	+136.14%	+17.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.0551 of 5 stars	3.3	1.0	0.0	2.5	1.7	0.6
ARDX Ardelyx	4.2872 of 5 stars	3.5	2.0	4.4	2.9	2.5	0.6
AVDL Avadel Pharmaceuticals	2.6299 of 5 stars	3.6	3.0	0.0	1.8	1.7	0.6
COGT Cogent Biosciences	3.4505 of 5 stars	4.4	3.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.67	Moderate Buy	$9.50	69.64% Upside
ARDX Ardelyx	3.00	Buy	$11.50	96.25% Upside
AVDL Avadel Pharmaceuticals	3.14	Buy	$18.67	36.25% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$18.70	59.01% Upside

Current Analyst Ratings Breakdown

Latest ALDX, ARDX, COGT, and AVDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	AVDL Avadel Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	ALDX Aldeyra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	AVDL Avadel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00
8/7/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $30.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/6/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $21.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
8/5/2025	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $14.00
7/18/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$22.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.92 per share	N/A
ARDX Ardelyx	$333.61M	4.23	N/A	N/A	$0.58 per share	10.10
AVDL Avadel Pharmaceuticals	$169.12M	7.87	N/A	N/A	$0.93 per share	14.73
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$0.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	11/6/2025 (Estimated)
ARDX Ardelyx	-$39.14M	-$0.23	N/A	18.90	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.03	N/A	228.33	N/A	-1.32%	-3.73%	-1.73%	N/A
COGT Cogent Biosciences	-$255.86M	-$1.78	N/A	N/A	N/A	N/A	-223.82%	-89.44%	N/A

Latest ALDX, ARDX, COGT, and AVDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
ARDX Ardelyx	1.44	4.30	4.03
AVDL Avadel Pharmaceuticals	N/A	2.79	2.38
COGT Cogent Biosciences	N/A	4.19	4.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
ARDX Ardelyx	58.92%
AVDL Avadel Pharmaceuticals	69.19%
COGT Cogent Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	8.50%
ARDX Ardelyx	4.80%
AVDL Avadel Pharmaceuticals	5.20%
COGT Cogent Biosciences	7.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.81 million	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
AVDL Avadel Pharmaceuticals	70	97.10 million	92.05 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable

ALDX, ARDX, COGT, and AVDL Headlines

Recent News About These Companies

XTX Topco Ltd Cuts Stake in Cogent Biosciences, Inc. (NASDAQ:COGT)

August 16, 2025 | marketbeat.com

Knott David M Jr Takes $1.28 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT)

August 12, 2025 | marketbeat.com

Leerink Partnrs Has Negative Forecast for COGT Q3 Earnings

August 10, 2025 | americanbankingnews.com

Wedbush Has Pessimistic Outlook of COGT FY2025 Earnings

August 9, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Outlook for COGT Earnings

August 9, 2025 | marketbeat.com

Q3 Earnings Estimate for COGT Issued By Leerink Partnrs

August 9, 2025 | marketbeat.com

Wedbush Lowers Earnings Estimates for Cogent Biosciences

August 9, 2025 | americanbankingnews.com

Equities Analysts Issue Forecasts for COGT Q3 Earnings

August 9, 2025 | americanbankingnews.com

JPMorgan Chase & Co. Increases Cogent Biosciences (NASDAQ:COGT) Price Target to $30.00

August 8, 2025 | marketbeat.com

Leerink Partners Sticks to Their Buy Rating for Cogent Biosciences (COGT)

August 8, 2025 | theglobeandmail.com

Q3 EPS Estimate for Cogent Biosciences Decreased by Analyst

August 8, 2025 | marketbeat.com

Cogent Biosciences (COGT) Gets a Hold from Robert W. Baird

August 8, 2025 | theglobeandmail.com

HC Wainwright Has Lowered Expectations for Cogent Biosciences (NASDAQ:COGT) Stock Price

August 7, 2025 | marketbeat.com

Cogent Biosciences (NASDAQ:COGT) Posts Earnings Results, Beats Estimates By $0.01 EPS

August 6, 2025 | marketbeat.com

Cogent Biosciences price target lowered to $21 from $22 at H.C. Wainwright

August 6, 2025 | msn.com

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

August 5, 2025 | globenewswire.com

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 3, 2025 | marketbeat.com

Needham Reaffirms Their Hold Rating on Cogent Biosciences (COGT)

August 1, 2025 | theglobeandmail.com

Scotiabank Sticks to Its Buy Rating for Cogent Biosciences (COGT)

August 1, 2025 | theglobeandmail.com

Y Intercept Hong Kong Ltd Sells 31,538 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

July 31, 2025 | marketbeat.com

Cogent Biosciences (COGT) Expected to Announce Earnings on Tuesday

July 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, ARDX, COGT, and AVDL Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.60 +0.16 (+2.94%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$5.54 -0.06 (-1.07%)

As of 04:00 AM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Ardelyx NASDAQ:ARDX

$5.86 +0.05 (+0.86%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$5.82 -0.04 (-0.77%)

As of 08/19/2025 07:57 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Avadel Pharmaceuticals NASDAQ:AVDL

$13.70 +0.22 (+1.63%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$13.97 +0.27 (+1.97%)

As of 08/19/2025 07:51 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Cogent Biosciences NASDAQ:COGT

$11.76 -0.35 (-2.89%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$11.76 0.00 (0.00%)

As of 08/19/2025 06:09 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time